peptides
Tesamorelin 10mg
Tesamorelin is a GHRH analog studied for selective visceral fat reduction and lean mass support. It stimulates endogenous GH release in a pulsatile, physiologic pattern.
Research-observed benefits
- ›Visceral fat reduction
- ›Lean mass retention
- ›IGF-1 elevation
- ›Improved lipid profile
Findings reported in in-vitro / preclinical research literature. Not therapeutic claims.
Reconstitution helper
Suggested: 2 mL BAC water → 5.00 mg/mL
CAS Number
—
Purity
99%+
Molecular Formula
—
Stock
200 units
Order type
Purchase option
Quantity
Total
$80
For in-vitro research only. Not for human consumption, diagnostic, or therapeutic use. Storage at -20°C recommended for lyophilized peptides.
Tesamorelin — Full Research Breakdown
Tailored information for researchers. All content is for in-vitro / preclinical research context only — not medical advice.
Mechanism of Action
Stabilized 44-amino-acid GHRH analog. Binds GHRH-R on pituitary somatotrophs to amplify endogenous pulsatile GH release, raising IGF-1 within the physiologic range.
How It Helps
Selectively reduces visceral adipose tissue (VAT), preserves lean mass, and improves lipid markers — without the supraphysiologic GH spikes seen with exogenous HGH.
Half-Life
~26 minutes plasma; biological effects sustained via pulsatile GH release
Onset of Effects
IGF-1 rises within 2 weeks; VAT reduction measurable by week 13.
Administration
Subcutaneous, abdomen. Daily evening dose preferred to align with natural GH pulses.
Storage
Lyophilized: –20°C. Reconstituted: 2–8°C, use within 7 days for optimal potency.
Reconstitution Guide
10 mg vial + 1 mL BAC → 10 mg/mL (1 mg per 0.1 mL). 2 mL BAC → 5 mg/mL for finer titration.
Precise Dosing Protocols
Clinical reference dose
- Dose:
- 2 mg/day
- Frequency:
- Daily, evening SC
- Duration:
- 26 weeks
- Notes:
- NEJM 2007 protocol
Lower-frequency research
- Dose:
- 1 mg 5×/week
- Frequency:
- 5 days on / 2 off
- Duration:
- 12+ weeks
Stacks Well With
- ›CJC-1295 / Ipamorelin (synergistic GH pulse)
- ›BPC-157 (joint comfort)
- ›MOTS-c (metabolic)
Research-Observed Side Effects
- •Injection-site redness
- •Transient fluid retention
- •Joint stiffness early in cycle
- •Glucose: monitor in research with insulin-resistance models
Translational Cautions
- •Active malignancy in human translation
- •Hypothalamic-pituitary axis pathology
Cycling Guidance
Continuous 26-week arcs with 4-week off-periods are typical to reassess IGF-1 baseline.
Research Highlights
- ▸Falutz et al. NEJM 2007: ~15% VAT reduction at 26 weeks.
- ▸Sustained IGF-1 elevation 80–100% above baseline.
- ▸Pilot data: improved executive-function markers in older adult cohorts.